Page 1 | Search Results | Blood | American Society of Hematology

1-11 of 11

Sort by

Sort Order Select

Journal Articles

Ibrutinib, Single Agent or in Combination with Dexamethasone, in Patients with Relapsed or Relapsed/Refractory Multiple Myeloma (MM): Preliminary Phase 2 Results

Ravi Vij, MBBS, MD, Carol Ann Huff, MD, William I. Bensinger, MD, David S. Siegel, MD PhD, Sundar Jagannath, MD, Jesus Berdeja, MD, Nikoletta Lendvai, MD PhD, Daniel Lebovic, MD, Larry D. Anderson, MD PhD, Caitlin L. Costello, MD, Keith E. Stockerl-Goldstein, MD, Jacob P. Laubach, MD, Laurence Elias, MD, Fong Clow, ScD, Maria Fardis, PhD MBA, Thorsten Graef, MD PhD, Elizabeth Bilotti, MSN, Paul G. Richardson

Blood (2014) 124 (21): 31.

https://doi.org/10.1182/blood.V124.21.31.31

Published: 2014

Journal Articles

A Phase II Trial Evaluating the Safety of Rapid Infusion Ofatumumab (OFA) in Patients (pts) with Previously Treated Chronic Lymphocytic Leukemia (CLL)

William B. Donnellan, MD, Jesus Berdeja, MD, Dianna Shipley, MD, Edward Arrowsmith, MD MPH, David Wright, MD, Scott Lunin, MD, Richard H. Brown, MD, James Essell, MD, Ian Flinn

Blood (2014) 124 (21): 3336.

https://doi.org/10.1182/blood.V124.21.3336.3336

Published: 2014

Journal Articles

Pharmacokinetics and Safety of Elotuzumab in Combination with Lenalidomide and Dexamethasone in Patients with Multiple Myeloma and Various Levels of Renal Function: Results of a Phase 1b Study

Jesus Berdeja, MD, Sundar Jagannath, MD, Jeffrey Zonder, MD, Ashraf Badros, MD, Jonathan L. Kaufman, MD, Robert Manges, MD, Mark Lynch, PhD, Eric Bleickardt, MD, Prashni Paliwal, PhD, Ravi Vij, MD

Blood (2014) 124 (21): 2119.

https://doi.org/10.1182/blood.V124.21.2119.2119

Published: 2014

Journal Articles

A Single-Arm, Open-Label, Multi-Center Phase I/II Study Of The Combination Of Panobinostat and Carfilzomib In Patients (pts) With Relapsed Or Relapse/Refractory Multiple Myeloma (MM)

Jesus Berdeja, MD, Michael Savona, MD, Joseph R Mace, MD, Lowell Hart, MD, James Essell, MD, Rami Owera, MD, Edward Arrowsmith, MD, MPH, Ian Flinn, MD, PhD

Blood (2013) 122 (21): 1937.

https://doi.org/10.1182/blood.V122.21.1937.1937

Published: 2013

Journal Articles

Array-Based Comparative Genomic Hybridization (aCGH) In Myelofibrosis Reveals Divergent Genetic Copy Number Alterations Among Patients With Post-Essential Thrombocythemia-Myelofibrosis/Post-Polycythemia Rubra Vera-Myelofibrosis (PET-MF and PPV-MF) and Patients With Idiopathic Myelofibrosis

Michael Savona, MD, Zeqiang Ma, PhD, Laura DeBusk, PhD, Pranil Chandra, DO, Shile Liang, PhD, R. Seth Cooper, MD, Eric Raefsky, MD, Victor Gian, MD, Richard Hockett, MD, Jesus Berdeja, MD, P. Alan Lennon, PhD

Blood (2013) 122 (21): 5266.

https://doi.org/10.1182/blood.V122.21.5266.5266

Published: 2013

Journal Articles

ACY-1215, a Selective Histone Deacetylase (HDAC) 6 Inhibitor, In Combination With Lenalidomide and Dexamethasone (dex), Is Well Tolerated Without Dose Limiting Toxicity (DLT) In Patients (Pts) With Multiple Myeloma (MM) At Doses Demonstrating Biologic Activity: Interim Results Of a Phase 1b Trial

Andrew Yee, Peter Vorhees, MD, William I. Bensinger, MD, Jesus Berdeja, MD, Jeffrey G Supko, PhD, Paul G. Richardson, MD, Simon S Jones, PhD, Gretchen Patrick, Catherine Wheeler, MD, Noopur Raje, MD

Blood (2013) 122 (21): 3190.

https://doi.org/10.1182/blood.V122.21.3190.3190

Published: 2013

Journal Articles

Bendamustine, Bortezomib and Dexamethasone (BBD) As First-Line Treatment Of Patients (Pts) With Multiple Myeloma Who Are Not Candidates For High Dose Chemotherapy

Jesus Berdeja, MD, Michael Savona, MD, Luis Chu, MD, James Essell, MD, Patrick Murphy, MD, Todd Bauer, MD, Eric Raefsky, MD, Ralph V. Boccia, MD, Ian Flinn, MD, PhD

Blood (2013) 122 (21): 3193.

https://doi.org/10.1182/blood.V122.21.3193.3193

Published: 2013

Journal Articles

The Multiple Myeloma Research Consortium (MMRC): A Model For Accelerating Development Of Novel Therapies For Multiple Myeloma

Beverly Harrison, Kenneth C. Anderson, MD, Noopur Raje, MD, Paul Richardson, MD, Diane Warren, Ajai Chari, MD, Sundar Jagannath, MD, Lisa La, Jesus Berdeja, MD, Meredith Zimlich, Joseph W. Fay, MD, Sheila Powell, RN, Craig C Hofmeister, MD, Nita Williams, BS, Andrzej J. Jakubowiak, MD, PhD, Todd M. Zimmerman, MD, Kathryn McDonnell, Amrita Y. Krishnan, MD, Lupe Duarte, CCRC, Shaji K Kumar, MD, Ann Birgin, CRA, Sagar Lonial, M.D., Kenisha Baron, Thomas Martin, MD, Jeffrey L Wolf, MD, Geraldine Pelle-Day, Ph.D., Glenna Auerback, Gregory Orloff, MD, Nikki Hodge, Donna E Reece, MD, FRCPC, Suzanne Trudel, MD, Engin Gul, HonBSc, Vivek Roy, M.D., Michele Maharaj, RN, David S. Siegel, MD, PhD, Adolfo Aleman, A. Keith Stewart, Rachel Hagerty, Moshe Talpaz, MD, Roxane Collins, Ravi Vij, MD, Mark A. Fiala, BS, CCRP, Jeffrey Zonder, M.D., Silva Pregja, Sharon Goldberg, Joan Levy, PhD, Karen Dietz, Walter Capone, Daniel Auclair, PhD, Anne Quinn Young, Kathy Giusti, MBA

Blood (2013) 122 (21): 5388.

https://doi.org/10.1182/blood.V122.21.5388.5388

Published: 2013

Journal Articles

Combining Ibrutinib With Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP): Updated Results From a Phase 1b Study In Treatment-Naïve Patients With CD20-Positive B-Cell Non-Hodgkin’s Lymphoma (NHL)

Anas Younes, MD, Ian Flinn, MD, PhD, Jesus Berdeja, MD, Jonathan W. Friedberg, MD, Carla Casulo, MD, Catherine Thieblemont, MD, PhD, Franck Morschhauser, MD, PhD, Jason R. Westin, MD, Shobha Seetharam, PhD, Peter Hellemans, MD, Hans Smit, PhD, Ronald de Vries, MSc, Elisa Dauphinee, BSN, CRA, CCRP, Julie Badamo-Dotzis, PhD, Nele Fourneau, MD, Yasuhiro Oki, MD

Blood (2013) 122 (21): 852.

https://doi.org/10.1182/blood.V122.21.852.852

Published: 2013

Journal Articles

Twice-Weekly Oral MLN9708 (Ixazomib Citrate), An Investigational Proteasome Inhibitor, In Combination With Lenalidomide (Len) and Dexamethasone (Dex) In Patients (Pts) With Newly Diagnosed Multiple Myeloma (MM): Final Phase 1 Results and Phase 2 Data

Paul G. Richardson, MD, Craig C Hofmeister, MD, Cara A Rosenbaum, MD, Myo Htut, MD, David H. Vesole, MD, PhD, Jesus Berdeja, MD, Michaela Liedtke, MD, Ajai Chari, MD, Stephen D Smith, MD, Daniel Lebovic, MD, Deborah Berg, RN, MSN, Eileen Liao, Ph.D, Neeraj Gupta, Ph.D, Alessandra Di Bacco, Ph.D, Jose Estevam, BS, MS, Ai-Min Hui, Rachid Baz, MD

Blood (2013) 122 (21): 535.

https://doi.org/10.1182/blood.V122.21.535.535

Published: 2013

Journal Articles

R-Flurbiprofen, a Non-Steroidal Anti-Inflammatory Agent (NSAID) with Anti-Tumor Activity, Inhibits the Stromal-Induced Upregulation of Interleukin-8 in Chronic Lymphocytic Leukemia Cells.

Michael B. Lilly, MD, Jesus Berdeja, MD, C.S. Chen, MD, PhD, Svetlana Bashkyrova, Marina Zemskova, PhD

Blood (2004) 104 (11): 4794.

https://doi.org/10.1182/blood.V104.11.4794.4794

Published: 2004

NARROW

Ibrutinib, Single Agent or in Combination with Dexamethasone, in Patients with Relapsed or Relapsed/Refractory Multiple Myeloma (MM): Preliminary Phase 2 Results

A Phase II Trial Evaluating the Safety of Rapid Infusion Ofatumumab (OFA) in Patients (pts) with Previously Treated Chronic Lymphocytic Leukemia (CLL)

Pharmacokinetics and Safety of Elotuzumab in Combination with Lenalidomide and Dexamethasone in Patients with Multiple Myeloma and Various Levels of Renal Function: Results of a Phase 1b Study

A Single-Arm, Open-Label, Multi-Center Phase I/II Study Of The Combination Of Panobinostat and Carfilzomib In Patients (pts) With Relapsed Or Relapse/Refractory Multiple Myeloma (MM)

Array-Based Comparative Genomic Hybridization (aCGH) In Myelofibrosis Reveals Divergent Genetic Copy Number Alterations Among Patients With Post-Essential Thrombocythemia-Myelofibrosis/Post-Polycythemia Rubra Vera-Myelofibrosis (PET-MF and PPV-MF) and Patients With Idiopathic Myelofibrosis

ACY-1215, a Selective Histone Deacetylase (HDAC) 6 Inhibitor, In Combination With Lenalidomide and Dexamethasone (dex), Is Well Tolerated Without Dose Limiting Toxicity (DLT) In Patients (Pts) With Multiple Myeloma (MM) At Doses Demonstrating Biologic Activity: Interim Results Of a Phase 1b Trial

Bendamustine, Bortezomib and Dexamethasone (BBD) As First-Line Treatment Of Patients (Pts) With Multiple Myeloma Who Are Not Candidates For High Dose Chemotherapy

The Multiple Myeloma Research Consortium (MMRC): A Model For Accelerating Development Of Novel Therapies For Multiple Myeloma

Combining Ibrutinib With Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP): Updated Results From a Phase 1b Study In Treatment-Naïve Patients With CD20-Positive B-Cell Non-Hodgkin’s Lymphoma (NHL)

Twice-Weekly Oral MLN9708 (Ixazomib Citrate), An Investigational Proteasome Inhibitor, In Combination With Lenalidomide (Len) and Dexamethasone (Dex) In Patients (Pts) With Newly Diagnosed Multiple Myeloma (MM): Final Phase 1 Results and Phase 2 Data

R-Flurbiprofen, a Non-Steroidal Anti-Inflammatory Agent (NSAID) with Anti-Tumor Activity, Inhibits the Stromal-Induced Upregulation of Interleukin-8 in Chronic Lymphocytic Leukemia Cells.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only